More recently, co-mutations of PTEN have been associated with significantly shorter PFS in a Korean cohort of EGFRM+ NSCLC patients receiving osimertinib as second line following initial EGFR-TKI failure (2.6 vs. 10.3 months for cases without PTEN co-mutations; p = 0.001; HR = 5.8 in multivariate analysis) [124]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.